Donate - Поддержка фонда Ф.Б.Березина

Изяслав Лапин. Стресс. Тревога. Депрессия. Алкоголизм. Эпилепсия. 20

Список иноязычной литературы M-Z


Macenzie G. M., Jenner P., Marsden C. D. The effect of nitric oxide synthase inhibition on quinolinic acid toxicity in the rat striatum. — Neuroscience. — 1995. — V. 67. — P. 357-372.

Maeda K, Kaneda H., Whetsell W. Q., Tammiga C. A. Neurochemical and metabolic consequences of elevated cerebrospinal fluid quinolinic acid concentrations in rat brain. — Neurosci. Res. -1997.-V. 29.-P. 303-310.

Maes M., Basmans E., Lin A et al. Immune alterations and psychological stress in humans. XXIst CINP Congress (Glasgow, July 12-16,1998). — 1998. — Final Programme. P. 195.

Mandel P., Pasantes-Morales H. Taurine in the nervous system. -Reviews of neuroscience. -V. 3 (eds. Ehrenpreis S., Kopin I.). — Raven Press. — New York. — 1978. — P. 157-193.

Mangoni A From the lactate-pyruvate ratio in schizophrenia to tryptophan pyrrolase activity in depression. — Ban Т., Healy D., Shorter E. (eds.) The Rise of Psychopharmacology. — Animula. -Budapest. — 1998. — P. 255-257.

Manning B. D., Mason M. Kynurenine metabolism in rats: some hormonal factors affecting enzyme activities. — Life Sci. -1975. -V. 17. — P. 225-232.

Marchesi G. F., Quattrini A., Scarpino O., Dellantonio R. Effetti terapeutici della taurina nella epilessia. Indagine clinica e polifisiog-rafica. — Rivista Patol. Nervosa Mentale (Firenze). — 1975. — V. 96. -P. 166-184.

Marcucci F., Airoldi M. L., Mussini E. et al. Brain levels of metrazol determined with new gas chromatographic procedure. — Eur. J. Pharmacol. — 1971. — V. 16. — P. 219.

Marrannes R., Wauquier A. Episodic barrel rotations induced by intrastriatal injection of quinolinic acid in rats. Inhibition by anticonvulsants. — Pharmacol. Biochem. Behav. — 1988. — V. 31. -P. 153-162.

Martin P. Animal models sensitive to anti-anxiety drugs. — Acta Psychiatrica Scand. — 1998. — V. 98. — Suppl. 393. — P. 74-80.

Martin A., Heyes M. P., Salazar A M. etal. Impaired motor-skill learning, slowed reaction time, and elevated cerebrospinal fluid quinolinic acid in a subgroup of HIV-infected individuals. Neuropsychology. — 1993. — V. 7. — P. 149-157.

Martin D., Lodge D Biphasic effect of quinolinate on frog spinal, but not rat cortical, neurones: N-methyl-D-aspartate-like depolarisation and a novel type of hyperpolarisation. Neurosci. Letters. -1987.-V. 75.-P. 175-180.

Martinsons A, RudziteV., Jurika E. et al. The relationship between kynurenine, catecholamines, and arterial hypertension in me-sangioproliferative glomerulonephritis. — Recent Advances in Tryptophan Research. Try [tophan and Serotonin Pathways (Eds. Fi-lippini G. A., Costa C. V.L., Bertazzo A.). — Plenum Press. — New York-London. — 1996. — P. 417-419.

Mayer M. L., Miller R. J. Excitatory amino acid receptors, second messengers and regulation of intracellular Ca2+ in mammalian neurons. -Trends in Pharmacol. Sci. -1990. -V. 11. — P. 254-260.

Mayo К. M., Falkowski W., Jones C.A H. Caffeine: use and effects in long-stay psychiatric patients. — Brit. J. Psychiatry. -1993. -V. 162. — P. 543-545.

McCreary A. C., Handley S. L. Kynurenine potentiate the DOI head shake in mice. — Psychopharmacology. — 1995. — V. 9. -P. 69-70.

McGeer E. G., Singh E. Neurotoxic effects of endogenous materials: quinolinic acid, 1-pyroglutamic acid and thyroid releasing hormone. — Exp. Neurol. — 1984. — V. 86. — P. 410-413.

McLennan H. A comparison of the effects of N-methyl-D-aspartate and quinolinate on central neurons of the rat. — Neurosci. Lett. -1984.-V. 46.-P. 157-160.

Meldrum B. Neurotransmitter amino acids in epilepsy. Elec-troencephalogr. Clin. Neurophysiol. — 1987. -V. 39 (Suppl.). -P. 191-199.

Meldrum B. Future prospects for EAA antagonists (Chapter 15). — Excitatory amino acid antagonists (Ed. B. S. Meldrum). -Blackwell Sci. Publ. — Oxford. — 1991. — P. 327-338.

Mendelson S. D., Lee N., Gorzalka В. B. Intraventricular administration of 1-kynurenine and kynuramine facilitates lordosis in the female rat. — Eur. J. Pharmacol. — 1987. — V. 142. — P. 447-451.

Meyerhoff J. L., Slusher B. S., Yourick D. L. et al. Genetically epilepsy-prone rats have increased cortical activity of depeptidase which may liberate glutamate. Epilepsia. — 1991. — V. 32. Suppl. 1. —P. 60.

McCreary А. С., Handley S. L. Kynurenine potentiate the DOI head shake in mice. — Psychopharmacology. -1995. -V. 9. — P. 69-70.

McLennan H. A comparison of the effects of N-methyl-D-aspar-tate and quinolinate on central neurons of the rat. — Neurosci. Letters. — 1984. — V. 46. — P. 157-160.

McLood D. R., Hoehn-Saric R., Porges S. W., Kowakski P. A., Clark С. M. Therapeutic effects of imipramine are counteracted by its metabolite, desipramine, in patients with generalized anxiety disorder. -J. Clin. Psychopharmacology. — 2000. — V. 20. — P. 615-621.

Miliasius A M., Grinevicius К. — K.A., Lapin I. P. Effect of quinolinic acid on wakefulness and sleep in the rabbit. — J. Neural Transmission. — 1990. — V. 82. — P. 67-73.

Miranda A. F., Boegman R. J., Beninger R. J., Jhamandas K. Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid. -Neuroscience. — 1997. — V. 78. — P. 967-976.

Miranda A. F., Sutton M. A., Beninger R. J., Jhamandas K., Boegman R. J. Quinolinic acid lesion of the nigrostriatal pathway: effect of turning behavior and protection by elevation of endogenous kynurenic acid in Rattus norvegicus. — Neurosci. Lett. -1999. — V. 262. -No. 2. — P. 81-84.

Misztal M., FrankiewiczT., Parsons C. G., Danysz W. Learning deficits induced by chronic intraventricular infusion of quinolinic acid — Protection by MK-801 and memantine. — Eur. J. Pharmacol. -1996.-V. 295.-P. 1-8.

Misztal M., Skagielkramska J., Niewiadomska G., Danysz W. Subchronic intraventricular infusion of quinolinic aicd produces working memory impairment — A model of progressive excitotoxicity. — Neuropharmacology. — 1996. — V. 35. — P. 449-458.

MoffettJ. R., Espey M. G„ Gaudet S. J., Namboodril M.A A. Antibodies to quinolinic acid reveal localization in select immune cells rather than neurons or astroglia. — Brain Res. — 1993,- V. 623. -P. 337-340.

Mohler H. Benzodiazepine receptors: are there endogenous ligandsin the brain?-Trends in Pharmacol. Sci. — 1981.-V. 2,-P. 116-119.

Moller S. E. Pharmacokinetics of tryptophan, renal handling of kynurenine and the effect of nicotinamide on its appearance in plasma and urine following 1-tryptophan loading of healthy subjects. -Eur. J. Clin. Pharmacol. — 1981. — Y. 21. — P. 137-142.

Moller S. E. Tryptophan to competing amino acids ratio in depressive disorder: relation to efficacy of antidepressive treatment. -Acta Psychiatrica Scandinavica. -1985. — Suppl. 325. — V. 72. — 31 p.

Moller S. E., Amdisen A Plasma neutral amino acids and depression: variation during acute and prolonged treatment with L-tryptophan. — Biol. Psychiatry. — 1979. — V. 14. — P. 131-139.

Moller S. E., Kirk L. The effect of allopurinol on the kynurenine formation in human following a tryptophan load. — Acta Vitaminology et Enzymologica. — 1978. — V. 32. — P. 159-162.

Moller S. E., Kirk L., Fremming К. H. Plasma amino acids as an index for subgroups in manic depressive psychosis: correlation to effect of tryptophan. — Psychopharmacology. — 1976. — V. 49. -P. 205-213.

Moller S. E., Kirk L., Honore P. Relationship between plasma ratio of tryptophan to competing amino acids and the response to L-tryptophan treatment in endogenously depressed patients. — J. Affective Disorders. — 1980. — V. 2. — P.47-59.

Moller S. E., Kirk L., Honore P. Tryptophan tolerance and metabolism in endogenous depression. — Psychopharmacology. -1982.-V. 76.-P. 79-83.

Monaghan D. Т., Beaton J. A. Quinolinate differentiates between forebrain and cerebellar NMDA receptors. — Eur. J. Pharmacol. -1991.-V. 194.-P. 123-125.

Moncada S., Higgs A., Furchgott R. et al. XIV Int. Union of Pharmacology Nomenclature in Nitric Oxide Research. — Pharmacol. Reviews. — 1997. — V. 49. — P. 137-142.

Montenero A S. Sulla tossicita e tollerabilita del triptofano e suoi metaboliti.- Actavitaminol. enzymol. (Milano).-1978.- V. 32.-P. 188-194.

Moore P., Landolt H. P., Seifritz E., Clark C. et al. Clinical and physiological consequences of rapid tryptophan depletion. — Neuropsychopharmacology. — 2000. — V. 23. — P. 601-622.

Morgan P. F. Is quinolinic acid an endogenous excitotoxin in alcohol withdrawal? — Medical Hypotheses. — 1991. — V. 36. —P. 118-121.

Moroni F. Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. — Eur. J. Pharmacol. -1999.-V. 375.-P. 87-100.

Moroni F., Alesiani M., Galli A et al. Thiokynurenates: a new group of antagonists of the glycine modulatory site of the NMDA receptor. — Eur. J. Pharmacol. — 1991. — V. 199. — P. 227-232.

Moroni F., Lombardi G., Carla V. et al. Increase in the content of quinolinic acid in cerebrospinal fluid and frontal cortex of patients with hepatic failure. — J. Neurochemistry. — 1986. — V. 47. -P. 1667-1671.

Moroni F., Lombardi G., Moneti G., Aldino C. The excitotoxin quinolinic acid is present in the brain of several mammals and its cortical content increases during aging process. — Neurosci. Lett. -1984.-V. 47.-P. 51-55.

Muller P. D., Schwarz M., Riedel M. et al. Cytokines and schizophrenia: effects of antipsychotic drugs. — XXIst CINP Congress (Glasgow, July 12-16, 1998). — 1998. — Final Programme. — P. 195.

Munoz-Hoyos A, Molino-Carballo A., Rodriguez-Caberas Т., Uberos-FernandezJ., Ruiz-Cosano C., Acuna-Castrovieje D. Relationship between methoxyindole and kynurenine pathway metabolites in plasma and urine in children suffering from febrile and epileptic seizures. — Clin. Endocrinol. — 1997. -V. 47. — P. 667-677.

Nakamura Т. A, Yamada K., Hasegawa Т., Nabeshima T. Possible involvement of nitric oxide in quinolinic acid-induced convulsions in mice. — Pharmacol. Biochem. Behav. — 1995. — V. 51. -P. 309-312.

Nanba H., Kawata K., Saito S. Effect of gamma-aminobutyric acid on the alcohol withdrawal syndrome in mice. — Nihon Univ. J. Med. — 1980. — V. 22. — P. 181-193.

Naoi M., Ishiki R., Nomura Y., Hasegawa S., NagatsuT. Quinolinic acid: an endogenous inhibitor specific for type В monoamine oxidase in human brain synaptosomes. — Neurosci. Letters. -1987. -V. 74. — P. 232-236.

Naranjo C. A., Bremmer К. E. Drugs attenuating alcohol consumption in humans through effects on various neurotransmitter systems. — The Pharmacology of Alcohol Asbuse (ed. Kranz-ler H. R.). — Chapter 15. — Berlin. — Springer. — 1995. — P. 363-393.

Neumeister A, Kasper S., Rosenthal N. E. Monoamine depletion in light therapy-responders with seasonal affective disorders. -XXIst CINP Congress (Glasgow, July 1998) — Abstracts. — P. 57.

Nicholls D., Attwell D. The release and uptake of excitatory amino acids. — Trends in Pharmacol. Sci. — 1990. — V. 11. -P. 462-468.

Niles L. Melatonin interaction with the benzodiazepine-GABA receptor complex in the CNS. Kynurenine and Serotonin Pathways. Progress in tryptophan Research (eds. Schwarcz R., Young S., Brown R.R). — Plenum Press. — New York. — 1991. — P.267-280.

Nomura J. Effect of stress and psychotropic drugs on rat liver tryptophan pyrrolase. — Endocrinology. -1965. — V. 76. — P. 1190-1194.

Norman А В., Ford L. M., Sanberg P. R. Differential loss of neurochemical markers following quinolinic acid-induced lesions of rat striatum. — Exper. Neurology. — 1991. — V. 114. — P. 132-135.

Nottet Н. S.L.M., Flanagan Е. М., Flanagan С. R. et al. The regulation of quinolinic acid in human immunodeficiency virus infected monocytes. — J. Neurovirology. — 1996. — V. 2. — P. 111-117.

Nozaki K., Beal M. F. Neuroprotective effects of 1-kynurenine on hypoxia-ishemia and NMDA lesions in neonatal rats. — J. Cerebral Blood Flow and Metabolism. — 1992. — V. 12. — P. 400-407.

Ogawa Т., Matson W. R., Beal M. F. et al. Kynurenine pathway abnormalities in Parkinson's disease. — Neurology. -1992. — V. 42. -P. 1702-1706.

Okuno E., Du F., IshikawaTet al. Purification and characterization of kynurenine-pyruvate aminotransferase from rat kidney and brain. — Brain Res. — V. 534. — P. 37-44.

Oravec M., Sourkes T. L. The influence of a-methyltryptophan and some tryptophan metabolites on hepatic glycogenesis. — Biochemistry. — 1967. — V.6. — P. 2788-2794.

Oreilly R. L, Davis B. A. Phenylethylamine and schizophrenia. -Progress in Neuro-Psychopharmacology and Biological Psychiatry. -1994.-V. 18.-P. 63-76.

Orlando L. R., Standaert D. G., Penney J. В., Young A B. Meta-botropic receptors in excitotoxicity: (S)-4-carboxy-3-hydroxyphe-nylglycine (S)-4-C3=HPG) protects against rat striatal quinolinic acid lesions. — Neurosci. Lett. — 1995. -V. 200. — P. 109-112.

Orlikov А В., Prakhie I. В., Ryzov I. V. Kynurenine in blood plasma and DST in patients with endogenous anxiety and endogenous depression. — Biol Psychiatry. — 1994. — V. 36. — P. 97-102. •

Orlikov A Ryzov I. Caffeine-induced anxiety and increase of kynurenine concentration in plasma of healthy subjects: a pilot study. -Biol. Psychiatry. — 1991. -V. 29. — P. 391-396.

Parks C. L., Robinson P. S., Sibille E. et al. Increased anxiety in mice lacking the serotonin (1A) receptor. Proc. Nat. Acad. Sci. USA -1998. — V. 95. — № 18. — P. 10734-10739.

Paykel E. S. Causal relationships between clinical depression and life events. — Stress and Mental Disorder (eds. Barrett J. E., Rose R. M., Klerman G. L.). — Raven Press. — New York. — 1979. -P. 71-86.

Pearson S. J., Reynolds G. P. Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease. — Neu-rosci. Lett. — 1992. — V. 144. — P. 199-201.

Pelliciari R, Natalini В., Costantino G. et al. Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl) alanine, a potent inhibitor of kynurenine-3-hydroxylase. — J. Med. Chem. — 1995. -V. 37. — P. 647-655.

Pemberton L. A., Kerr S. J., Smythe G., Brew B. J. Quinolinic acid production by macrophages stimulated with IFN-c, TNF-a and IFN-a. — J. Interferon and Cytokin Res. — 1997. — V. 10. — P. 589-596.

Perez Navarro E., Albreich J., Arenas E., Calvo N., Marsal J. Nerve growth factor and basic fibroblast growth factor protect cholinergic neurons against quinolinic acid excitotoxicity in rat neostriatum. — Eur. J. Neuroscience. — 1994. — V. 6. — P. 706-711.

Perkins M. N., Stone T. W. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. — Brain Res. -1982. — V. 247. -P. 184-187.

Perkins M. N., Stone T. W. On the interaction of 2-ami-no-7-phosphono-heptanoic acid and quinolinic acid in mice. — Eur. J. Pharmacol. — 1983a. — V. 89. — P. 297-300.

Perkins M. N.. Stone T. W. Pharmacology and regional variations of quinolinic acid — evoked excitations in rat central nervous system. J. Pharmacol. Exp. Ther. — 1983b. — V. 226. — P. 551-557.

Perkins M. N., Stone T. W. A study of kynurenic acid and excitatory amino acids in the rat hippocampus. — J. Physiol. (London). -1984.-V. 72.-P. 118.

Perkins М. N.. Stone Т. W. Actions of kynurenic acid and quinolinic acid in the rat hippocampus in vivo. — Exper. Neurology. -1985.-V. 88.-P. 570-579.

Peters S., Choi D. W. Quinolinate is a weak excitant of cortical neurons in cell culture. — Brain Res. — 1987. — V. 420. — P. 1-10.

Peterson S. L. 7-Cholorokynurenic acid antagonizes the anticonvulsant activity of D-cycloserine in maximal electroshock seizures. Epilepsy Research. — 1992. — V. 13. — P. 73-81.

Peterson S. L. Diazepam potentiation by glycine in pentylenetetrazol seizures is antagonised by 7-chlorokynurenic acid. — Pharmacol. Biochem. Behav. — 1994. -V. 47. — P. 241-246.

Pfefferkorn E. R., Rebhun S., Eckel M. Characterization of an indole-amine-2,3-dioxygenase induction by gamma-interferon in cultured human fibroblasts.-J. Interferon Res. — 1986. — V. 6. -P. 267-279.

Piesche L, Hilse H., Oehlke J., Schrotter E., Oehme P. Substi-tuierte Picolinsauren als DBH-Inhibitoren. — Pharmazie. — 1983. -Bd. 38. — H.5. — S. 335-338.

Pinelli A., Govoni S., Ossi C. et al. Kynurenine may directly interact with GABA receptors in rat brain. — Pharmacology. -1985. -V. 30. — P. 255-258.

Pinelli A., Ossi C., Colombo R., et al. Experimental convulsions in rats induced by intravenricular administration of kynurenine and structurally related compounds. — Neuropharmacology. — 1984. -V. 23. — P. 333-337.

Pinsky C., Glavin G. В., Rose R. Kynurenic acid protects against neurotoxicity and lethality of toxic extracts from contamined atlan-tic coast mussels. — Progress Neuro-Psychopharmacol. — 1989. -V. 13. — P. 595-598.

Pittaluga A, Vaccari D., Raiteri M. The «kynurenate test», a biochemical asay for putative cognition enhancers. — J. Pharmacol, exp. ther. — 1997. — V. 283. — P. 82-90.

Plata-Salaman С. Cytokine action in the brain: behavioral-mo-lecular interface. — XXIst CINP Congress (Glasgow, July 12-16, 1998). — 1998. — Final Programme. — P. 169.

Poeggeler В., Rassoulpour A., Guidetti P., Wu H. Q., Schwarcz R Dopaminergic control of kynurenate levels and N-methyl-D-aspartate toxicity in the developing rat striatum. — Developmental Ne-uroscience. — 1998. -V. 20. — P. 146-153.

Politi V., Lavaggi M. V., De Luca G., Gorini A The role of transamination in the pharmacological effects of indole-3-pyruvic acid. -Kynurenine and Serotonin Pathways. Progress in Tryptophan Research (eds. Schwarcz R, Young S. N., Brown R. R). — Advances in Exp. Medicine and Biology. — V. 294. — Plenum Press. — New York. -1991. — P. 603-605.

Politi V., Lavaggi M. V., DiStazio G., Margonelli A Indole-3-руruvic acid as a direct precursor of kynurenic acid — Kynurenine and Serotonin Pathways. Progress in Tryptophan Research (eds. Schwarcz R, Young S. N., Brown R R). — Advances in Exp. Medicine and Biology. — V. 294. — Plenum Press. — 1991. — P. 515-518.

Pomfret D. W., Schenk K. W., Fludzinski P. Cohen M. L Interaction of 5-hydroxykynuramine, L-kynurenine and kynuramine with multiple serotonin receptors in smooth muscle. — J. Pharmacol, exp. Ther. — 1987. — V. 241. — P. 465-471.

Popoli P., Caporali M. G., Pessola A, Scotti De Carolis A. Behavioral and EEG correlates of quinolinic acid-induced striatal lesions in rats (A model of Huntington's disease). — Neurosci. Lett. -1992. -V.43 Suppl. — P.590.

Popoli P., Pezzola A, Domenici M. R. et al. Behavioral and electrophysiological correlates of the quinolinic acid rat model of Huntington disease. — Brain Res. Bull. — 1994. — V. 35. — P. 329-336.

Price J. M. Factors which alter the metabolism of tryptophan. -Med. J. of Osaka University. — 1968. — V. 19. — № 1. — P. 31-33.

Price J. M., Brown R R, Yess N. Testing of functional capacity of Tryptophan-Niacin pathway. — Adavances in Metabolic Disorders (eds. Levine R., Luft R.). — Academic Press. — London. — 1965. -P. 159-174.

Puzynski S., Bidzinski A., Hauptman M. et al. Przemiana tryptofanu I katecolamin w chorobie afektywnej dwubiegunowej. Psychiatria Polska. — 1978. — V. 12. — № 3. — P. 301-309.

Rabinoff M. Possible role of macrophage metabolic products including quinolinic acid and neopterin in the pathogenesis of inflammatory brain diseases. — Medical Hypotheses. — 1994. — V. 42. -P. 133-136.

Reinhard J. F. Altered tryptophan metabolism in mice with herpes simplex virus encephalitis: Increases in spinal cord quinolinic acid. — Neurochemical Res. — 1998. — Y. 23. — P. 661-666.

Reinhard J. F., Erickson J. В., Flanagan E. M. Quinolinic acid in neurological disease: opportunities for novel drug discovery. Advances in Pharmacology. — 1994. — V. 30. — P. 85-126.

Reinhard J. F., Flanagan E. M., Madge D. J., Iyer R, Salter M. Effetcs of 540C91 (E)-3-[(4′-pyridil)-vinyl]-lH-indole, an inhibitor of hepatic tryptophan dioxygenase, on brain quinolinic acid in mice. -Biochem. Pharmacol. — 1996. — V. 51. — P. 159-164.

Reinhard J. F., Flanagan E. M., Stokes В. T. Elevation of the neurotoxin quinolinic acid following spinal cord trauma. Brain Res. -1994.-V. 633.-P. 348-352.

Reiter R J., Melchiori D., Sewerynen F. et al. A review of the evidence supporting melatonin's role as an antioxidant. — J. Pineal Res.-1995.-V. 18.-P.2-11.

Richter A., Loscher W., Baran H., Gramer M. Increased levels of kynurenic acid in brains of genetically dystonic hamsters. — Develop. Brain Res. — 1996. — V. 92. — P. 111-116.

Rickards H., Dursun S. M., Farrar G. et al. Increased plasma kynurenine and its relationship to neopterin and tryptophan in Touret-te syndrome. — Psychol. Medicine. — 1996. — V. 26. — P. 857-862.

Robinson M. В., Anderson K. D., Koerner J. F. Kynurenic acid as an antagonist of hippocampal excitatory transmission. — Brain Res. — 1984. — V. 309. — P. 119-126.

Robinson M. В., Schulte M. K., Freund R. K., Johnson R. L., Koerner J. F. Structure-function relationships for kynurenic acid analogues at excitatory pathways in the rat hippocmpal slice. — Brain Res. -1986.-V. 361.-P. 19-24.

Roches J. S., Zumstein H. R., Fassler A, Scollo-Lavizzari G., Hosli L Effects of taurine, glycine and GABA on convulsions produced by strychnine in the rabbit. — Eur. Neurol. — 1979. — V. 18. -P. 26-32.

Rodgers R. J., Lee C., Shepherd J. K. Effects of diazepam on behavioral and antinociceptive responses to the elevated plus-maze in male mice depend upon treatment regimen and prior maze experience. — Psychopharmacology. — 1992. — V. 106. — P. 102-110.

Romijn H. J. The pineal, a tranqilizing organ? Life Sci. — 1978. -V. 23. — P. 2257-2274.

Romach M. K., Tomkins D. M. Clinical application of findings from animal research on alcohol self-administration and dependence. — The Pharmacology of Alcohol Sbuse (ed. Kranzler H. R). -Chapter 11. — Berlin. — Springer. — 1995. — P. 261-295.

Ross D. S., Fernstrom J. D., Wurtman R. J. The role of dietary protein in generating daily rhytms in rat liver tryptophan pyrrolase and tyrosine transaminase. — Metabolism. -1973. — V. 22. — P. 1175.

Rubin R. T. Multiple biochemical correlates of manic-depressi-ve illness. — J. Psychosomatic Res. — 1968. — V. 12. — P. 171-180.

Rudzite V. Impairment of kynurenine metabolism in cardiovascular disease. In: Schwarcz R., Young S. N., Brown R. R. (eds.) Kynurenine and Serotonin Pathways. Progress in Tryptophan Research. — 1991. — Plenum Press. — New York. — P. 663-667.

Rudzite V., Jurika E. Kynurenine and lipid metabolism. — Kynurenine and Serotonin Pathways. Progress in Tryptophan Research (eds. Schwarcz R., Young S. N.. Brown R. R.). — Advances in Experimental Medicine and Biology. — V. 294. — Plenum Press. — New York. — 1991. — P.463-466.

Rudzite V., Jurika E., Arajs J., Andrejev N. The relationship between kynurenine and arterial blood pressure. — Progress in Tryptophan and Serotonin Research (eds. Bender D. A., Joseph M. H., Kochen W„ Steinhart H.). de Gruyter.- Berlin. -1987. — P. 127-130.

Rudzite V., Sileniece G., Jirgensons J., SkardsJ., Zirne R., Dalmane A Bradyarhythmias and myocardial cell failure induced by kynurenine. Progress in Tryptophan and Serotonin Research (eds. Bender D. A, Joseph M. H., Kochen W., Steinhart H.). de Gruyter. -Berlin. — 1987. — P. 131-136.

Russi P., Carla V., Moroni F. Indolpyruvic acid administration increases the brain content of kynurenic acid. Is this a new avenue to modulate excitatory amino acid receptors in vivo? — Biochem. Pharmacol. — 1989. — V. 38. — P. 2405-2409.

Ruzicka В. В., Day R., Jhamandas К Quinolinic acid elevates striatal and pallidal Metenkephalin levels: the role of enkephalin synthesis and release. — Brain Res. — 1991. — V. 562. — P. 117-125.

Ryzov I. V., Tckhomelidze G. G., Lapin I. P. Alcohol withdrawal syndrome: correlation between blood plasma kynurenine and severity of symptoms. Xth Congress of Polish Pharmacol. Soc. (Bialys-tok, Sept. 6-9,1989). — Abstracts. — P. 272-273.

Sabator J., Ricos C. Abnormalities of tryptophan metabolism (Kynurenine pathway) found in a group of 830 mentally retarded children. — Clin. Chim. Acta. — 1974. — Y. 56. — P. 175-186.

Saito K., Chen C. Y., Masana M. et al. 4-chloro-3-hydroxyanthranilic acid, 6-chlorotryptophan and norharman attenuate quinolinic acid formation by interferon-g stimulated monocytes (THP-1) cells. -Biochem. J. — 1993. -V. 291. — P. 11-14.

Saito К, Markey S. P., Heyes M. P. Chronic effects ofc-interferon on quinolinic acid and indoleamine-2,3-dixygenase in brain of C57BL6 mice. — Brain Res. — 1991. — V. 546. — P. 151-154.

Saito K, Markey S. P., Heyes M. P. et al. Effects of immune activation on quinolinic acid and kynurenine pathway metabolism in the mouse. — Neuroscience. — 1992. — V. 52. — P. 25-39.

Saito K., Markey S., Heyes M. 6-chloro-D,Ltryptophan, 4-choloro-3-hydroxyanthranilic acid and dexamethasone attenuate quinolinic acid accumulation in brain and blood following systemic immune activation. — Neurosci. Lett — 1994. — V. 178. — P. 211-215.

Salle J., Laborit H. Action du L-tryptophane, de la DLrcynurenine administres separement et en association sur quelques epreuves interessant le systeme nerveux central. — Agressologie. -1972. -V. 13. — P. 253-256.

Sallee F. R, Sethuraman G., Sine L., Liu H. Yohimbine challenge in children with anxiety disorders. — Amer. J. Psychaitry. — 2000. -V. 157. — P. 1236-1242.

Saloman R M., Miller H. L., Delgado P. L., Charney D. The use of tryptophan depletion to evaluate central serotonin function in depression and other neuropsychiatry disorders. — Int. Clinical Psychopharmacology. — 1993. — V. 8. — Suppl. 2. — P. 41-46.

Sanberg P. R, Calderon S. F., Giordano M., Tew J. M., Norman A B. The quinolinic acid model of Hungtington's Disease: locomotor abnormalities. — Exper. Neurology. — 1989. — V. 105. — P. 45-53.

Samsonova M. L., Lapin I. P. Antidepressants and liver tryptophan pyrrolase activity. — Biochem. Pharmacol. — 1973. — V. 22. -P. 1499-1507.

Santamaria A, Rios С. MK-801, an N-methyl-D-aspartate receptor antagonist blocks quinolinic acid-induced lipid peroxidation in rat corpus striatum. — Neurosci. Lett. — 1993. — V. 159 — P. 51-54.

SaranT., KockiT., Urbanska E. M. et al. Metabotropic glutamate receptor agonists affect synthesis of 1-kynurenic acid in rat brain cortical slices. J. Physiol, and Pharmacol. — 1996. — V. 47. — № 3. -Suppl. 2. — P. 33-35.

Satoh T. Inhibitory effects of phenylhydrazine on the induction of tryptophan pyrrolase in rats. — Enzym biol. clin. — 1970. — V. 11. -P. 268-276.

Satoh Т., Moroi К Inhibition of tryptophan pyrrolase of rats by phenols, tryptophan analogs and hydrazine derivatives. — Chem. Pharm. Bull. — 1969. -V. 17. — P. 1560-1563.

Scharfman H. E., Goodman J. H. Effects of central and peripheral administration of kynurenic acid on hippocampal evoked responses in vivo and in vitro. — Neuroscience. -1998. — V. 86. — P. 751-764.

Scharfman H. E., Ofer A Pre treatment with L-kynurenine, the precursor to the excitatory amino acid antagonist kynurenic acid, suppresses epileptiform activity in combined enterinal/hippocam-pal slices. — Neurosci. Lett. — 1997. -V. 224. — P. 115-118.

Schmidt W„ Wolf G., Calka J., Schmidt H.H. W. Evidence for bidirectional changes in nitric oxide synthase activity in the rat striatum after excitoxically (quinolinic acid) induced degeneration. -Nuroscience. — 1995. -V. 67. — P. 345-356.

Schukit M. A., Hesselbrock V. Alcohol dependence and anxiety disorders: what is the relationship. — Amer. J. Psychiatry. — 1994. -V. 51. — P. 1723-1734.

Schukit M. A, Smith T. L., Daeppen J.-B. et al. Clinical relevance of the distinction between alcohol dependence with and without a physiological component. — Amer. J. Psychiatry. — 1998. — V. 155. -P. 733-740.

Schurr A, Rigor В. M. Quinolinate potentiates the neurotoxicity of excitatory amino acids in hypoxic neuronal tissue. — Brain Res. -1993.-V. 617.-P. 76-80.

Schwarcz R, Foster A C., French E. D. et al. Excitotoxic models for neurodegenerative disorders. — Life Sci. — 1984. — V. 35. -P. 19-32.

Schwarcz R, Kohler C. Differential vulnerability of central neurons of the rat to quinolinic acid. — Neurosci. Lett. — 1983. — V. 38. -P. 85-90.

Schwarcz R, Okuno E., Speciale C. et al. Neuronal degeneration in animals and man. — In: Neurotoxins and their pharmacological implications (ed. Jenner P.). — Raven. — NY. — 1987. — P. 19-32.

Schwarcz R, Okuno E., White R. J. Basal ganglia lesions in the rat: effects of quinolinic acid metabolism. — Brain Research. — 1989. -V. 490. — P. 103-109.

Schwarcz R., Poeggeler В., Rassoulpour A. et al. Regulation of kynurenic acid levels in the developing rat brain. — Amino Acids. -1998.-V. 14.-P. 243-250.

Schwarcz R, Shoulson I. Excitotoxins and Huntington's disease. — Animal Models of Dementia. — Alan R Iiss. — New York. -1987. -P. 39-68.

Schwarcz R, Speciale C., Okuno E. et al. Quinolinic acid: a pathogen in seizure disorders? Adv. Exp. Med. Biol. -1986. — V. 203. -P. 697-707.

Schwarcz R, Whetsell W. O., Mangano R M. Quinolinic acid: An endogenous metabolite that produces axon-sparing lesions in rat brain. Science. — 1983. -V. 219. — P. 316-318.

Sei Y., Fossom L., Gopping G., Skolnick P., Basile A S. Quinolinic acid protects rat cerebellar granule cells from glutamate-induced apoptosis. — Neurosci. Lett. — 1998. — V. 241. — P. 180-184.

Sei Y., Paul I. A, Saito K., Layar R., et al. Quinolinic cid levels in a murine retrovirus-induced immunodeficiency syndrome. — J. Neurochem. — 1996. — V. 66. — P. 296-302.

Sellers Е. М., Higgins G. A., Sobell М. В. 5-HTand alcohol abuse. — Trends in Pharmacol. Sci. — 1992. — V. 13. — P. 69-75.

Shear D. A., Dong J., HaikCreguer K. L. et al. Chronic administration of quinolinic acid in the rat striatum causes spatial learning deficits in a radial arm water maze task. — Exper. Neurology. -1998. -V. 150. — P. 305-311.

Shibata Y. On the regulation of tryptophan metabolism «via» kynurenine. — Acta vitaminol. enzymol. (Milano). — 1978. — V. 32. -P. 195-207.

Shopsin B. Enhancement of the antidepressant response to L-tryptophan by a liver pyrrolase inhibitor: a rational treament approach. — Neuropsychopharmacology. — 1978. — V. 4. — P. 188-192.

Shores M. M., Glubin Т., Cowley D. S., Dager S. R, Roy-Byrne P. P., Dunner D. L. The relationship between anxiety and depression: a clinical comparison of generalized anxiety disorder, disthymic disorder, panic disorder, and major depressive disorder. — Comprehensive Psychiatry. — 1992. — V. 33. — P. 237-244.

Silva R. R, Alpert M., Munnoz D. H., Singh S., Matzner F., Dummit S. Stress and vulnerability to posttraumatic stress disorder in children and adolescents. Amer. J. Psychaitry. — 2000. — V. 157. -P. 1229-1235.

Simon R. P., Young R S.K., Stout S., Cheng J. Inhibition of excitatory neurotransmission with kynurenate reduces brain edema in neonatal anoxia-Neurosci. Lett. — 1986. — V. 71. — P. 361-364.

Sinz E. H., Kochanek P. M., Heyes M. P. et al. Quinolinic acid increased in CSF and associated with mortality after traumatic brain injury. — J. Cerebral Blood Flow and Metabolism. -1998. -V. 18. -P. 610-615.

Slotnik В., Leonard С. M. A stereotaxic atlas of the albino mouse forebrain. — U.S. Dept. of Health, Education, Welfare. — Rockville. -1975. — P. 31-40.

Sluzewska A Cytokines and treatment of resistant depression. -CINP Congress (Glasgow, July 12-16, 1998). — 1998. — Final Programme. — P. 195.

Smeraldi E., Diaferia G., Erzegovesi S. et al. Tryptophan depletion in obsessive — compulsive patients. — Biol. Psychiatry. -1996. -V. 40. — P. 398-402.

Smith K. A, Clifford E. M., Hockney R. A, Clark D. M., Cowen P. J. Moroni F. Effect of tryptophan depletion in male and female volunteers: a pilot study. — HumanPsychopharmacololgy-Clinical and Experimental. — 1997. — V. 12. — P.lll-118.

Smith D. H., Okiyama K., Thomas M. J., Macintosh Т. K. Effects of excitatory amino receptor antagonists kynurenate and indole-2-carboxylic acid on behavioral and neurochemical outcome following experimental brain injury. — J. Neuroscience. — 1994. -V. 13. -P. 5383-5392.

Soda K., Tanizawa К Kynureninases: enzymological properties and regulation mechanisms. Advances in Enzymology. — 1979. -V. 49. — P. 1-40.

Song C., Connor Т., Merali Z et al. Behavioral, neurotransmitter and endocrine responses to cytokin administrations: the different role of cytokines in the neuroimmune modulations in rats. -CINP Congress (Glasgow, July 12-16, 1998). — 1998. — Final Programme. — P. 169.

Song C., Leonard В. E. Fundamentals of Psychoneuroimmunology. — Wiley &.Sons. — Chichester-New York. — 2000. — 285 p.

Song C., Maes M., Bosmans E., Scharpe S. Influence of psychological stress on immune-inflammatory variables in normal humans. -XXIst CINP Congress (Glasqow, July 1998). — Abstracts. — P. 135.

Southgate G. S., Daya S., Potgieter B. Melatonin plays a protective role in quinolinic acid-induced neurotoxicity in the rat hippocampus. -J. Chemical Neuroanatomy. -1998. -V. 14. — P. 151-156.

Southgate G. S., Daya S., Potgieter B. Melatonin reduces quinolinic acid lipid peroxidation in rat brain homogenate. — Metab. Brain Res. — 1999. — V. 14. — P. 165-171

Speciale C., Okuno E., Schwarcz R Increased quinolinic acid metabolism following neuronal degeneration in the rat hippocampus. — Brain Res. — 1987. — V. 436. — P. 18-24.

Speciale C., Ungerstedt U., Schwarcz R Systemic administration of kynurenine in the rat causes increases in the serum and brain content of quinolinic acid. — Neuroscience. — 1987. -V. 22S. -P. 1986.

Speciale C., Ungerstedt U., Schwarcz R Effect of kynurenine loading on quinolinic acid production in the rat: studies in vitro and in vivo. — Life Sci. — 1988. — V.43. — P. 777-786.

Speciale C., Ungerstedt U., Schwarcz R. Production of extracellular quinolinic acid in the striatum studied by microdialysis in unanesthetized rats. — Neurosci. Letters. — 1989. — V. 104. — P. 345-350.

Sperling M. R. Prolactin in partial epilepsy: an indicator of limbic seizures. — Ann. Neurol. — 1986. — V. 20. — P. 716-722.

Spiera H., Vallarino R Serum kynurenine in rhematoid arthritis. J. Clin. Investigation. — 1969. — V. 48. — P. 856-859.

Spinweber C. L., Ursin R, Hilbert R. P., Hildebrandt R. L. L-Tryptophan. Effects on daytime sleep latency and the waking EEG. — Electroencephalogr. Clin. Neurophysiol. -1983. -V. 55. -P. 652-661.

Steele R. J. et al. 7-chlorokynurenate, an antagonist of the glycine binding site on the NMDA receptor inhibits memory formation in day-old chicks (Gallus domesticus). — Behav. Neural. Biol. -1993. -V.60. — P.89-92.

Stephens D. N., Andrews J. S. N-methyl-D-aspartate antagonists in animal models of anxiety. — Frontiers in excitatory amino acid research (eds. Cavalheiro E. A., Lehmann J. L, Turski L.). -Alan R Liss Inc. — New York. — 1988. — P. 309-316.

Stephens D. N., Andrews J. S., Turski L., Schneider H. H. Excitatory amino acids and anxiety.- New Concepts in Anxiety (eds. Briley M., File S. E.). — CRC Press. Boca Raton, Florida. — 1991. -P. 366-381.

Stone T. W. Excitant activity of methyl derivatives of quinolinic acid on rat cortical neurons. — Brit. J. Pharmacol. — 1984. — V. 81. -P. 175-181.

Stone T. W. The relative potencies of (-)-2-amino-5-phosphono-valerate and (-)-2-2-amino-7-phosphonoheptanoate as antagonists of N-methylaspartate and quinolinic acids and repetitive spikes in rat hippocampal slices. — Brain Res. — 1986. — V. 381. — P. 195-198.

Stone T. W. Sensitivity of hippocampal neurons to kainic acid and antagonism by kynurenate. — Brit J. Pharmacol. -1990. — V. 101. -P. 847-852.

Stone T. W. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Revs. — 1993. — V. 45. — P. 309-379.

Stone T. W., Perkins M. N. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. — Eur. J. Pharmacol. -1981. -V. 72. -P. 411-412.

Sun M. K., Reis D. J. Intrathecal kynurenate but not benextramine blocks hypoxic sympathoexcitation in chemodenervated anaesthetized rats. — J. Autonom. Nerv. Syst. — 1994. — V. 47. -P. 141-150.

Suzuki S., Mori A. Regional distribution of tyrosine, tryptophan, and their metabolites in the brain of epileptic EL mice. — Neurochemical Res. — 1992. — V. 17. — P. 693-698.

Tabakoff В., Hoffman P. L. Biochemical pharmacology of ethanol. — Psychopharmacology; the third generation of progress (ed. Meltzer H. Y.). — New York. — Raven Press. — 1987. — P. 1521-1526.

Tada H., Morooka K., Arimoto K, Matsuo T. Clinical effects of allopurinol in intractable epilepsy. — Epilepsia 1991. — V. 32. — P. 279-283.

Tada Н., Yanagawa А, Могоока К. et al. Anticonvulsive effects of allopurinol on an experimental animal model of epilepsy. — Epilepsia. — 1991. — V. 32. — Suppl. 1. — P. 97.

Takikawa 0., Yoshida R., Kido R., Haiyashi O. Tryptophan degradation in mice initiated by indoleamine-2,3-dioxygenase. — J. biol. Chem. — 1986. — V. 261. — P. 3648-3653.

Tavares R. G. Quinolinic acid inhibits glutamate uptake into synaptic vehicles from rat brain. — Neuroreport. — 2000. — V. 11. -P. 249-253.

Ticku M. K., Mehta А К Effect of alcohol on GABA-mediated neurotransmission. — The Pharmacology of Alcohol Abuse (ed. Kranzler H. R.). — Berlin. — Springer. — 1995. — P. 103-119.

Tiedtke P. I., Bischoff C., Schmidt W.J. МК-801-induced stereotypy and its antagonism by neuroleptic drugs. — J. Neural transmission. — 1990. — V. 81. — P. 173-182.

Tikal K., Plevova J., Ilvizdosova J. Correlation between the monoamine content in the brain and surrenals, the level of 5-hydroxyin-dolacetic acid in brain, liver tryptophanpyrrolase activity and behavior of pairs of rats. — Activ. Nerv. Super. — 1977. — V. 19. -P. 250-251.

Toda N. Analysis of the effect of 5-hydroxykynuramine, a selective serotonin metabolite, on isolated cerebral arteries, aorta and atria. — J. Pharmacol, exp. Ther. — 1975. — V. 193. — P. 385-392.

TonohiroT., KanekoT., Tanabe M., Iwata N. Picolinic acid and indole-2-carboxylic acid: two types of glycinergic compounds modulate motor function differentially. — Gen. Pharmacology. -1997. — V. 28. — P.555-560.

Tsai G., Gastfriend D. R., Coyle J. T. The glutamatergic basis of human alcoholism. — Amer. J. Psychiatry. — 1995. — V. 152. -P. 332-340.

Tsai G. E., Ragan P., Chang R. et al. Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal. -Amer. J. Psychiatry. — 1998. -V. 155. — P. 726-732.

Tung C. S., Grenhoff J., SvenssonT. H. Kynurenate blocks the acute effects of haloperidol on midbrain dopamine neurons recorded in vivo. — J. Neural Transmission. — 1991. — V. 84. — P. 53-64.

Turski W. A, Kocki Т., Saran Т., Urbanska E., Schwarcz R. Kynurenic acid — an endogenous neuromodulator or inactive metabolite? Pol. J. Pharmacol. — 1996. — V. 48. — P. 543.

Tyor W. R., Glass J. D., Griffin J. W. Cytokine expression in the brain during AIDS. — Ann. Neurol. -1992. — V. 31. — P. 249-360.

Vaiva G., Boss V., Addesa G. Cottencin 0. et al. Low GABA levels and posttraumatic stress disorder. — The Int. J. Neuropsychopharmacol. — 2000. — V. 3. — Suppl. 1. — P. 296.

Vanecek J., Krebs V., Scheer E., BielekeT. Anote on an apparatus for intracerebral injections in conscious mice. — J. Amer. Pharmaceut. Ass. — 1960. — V. 49. — P. 178.

Vecsei L. Kynurenine and probenecid inhibit pentylenetetrazol-and NMDA-induced seizures and increase kynurenic acid concentration in the brain. — Brain Res. Bull. — 1992. — V. 28. -P. 233-238.

Vecsei L., Beal M. F. Influnce of kynurenine treatment on open-field activity, elevated plus-maze, avoidance behaviors and seizures in rats. — Pharmacology Biochemistry Behavior. — 1990. -V. 37. — P. 71-76.

Vecsei L., Beal M. F. Intracerebroventricular injection of kynurenic acid but not kynurenine, induces ataxia and stereotyped behavior in rats. — Brain Res. Bull. — 1990. — V. 25. — P. 623-627.

Vecsei L., Beal M. F. Comparative behavioral and pharmacological studies with centrally administered kynurenine and kynurenic acid in rats. — Eur. J. Pharmacol. — 1991. — V. 196. — P. 239-246.

Vecsei L., Beal M. F. Huntington's disease, behavioral disturbances, and kynurenines. Preclinical findings and therapeutic perspectives. — Biol. Psychiatry. — 1996. — V. 39. — P. 1061-1063.

Vezzani A, Schwarcz R. A noradrenergic component of quinolinic acid-induced seizures. — Exper. Neurology — 1985. — V. 90. -P. 254-258.

Vezzani A, Ungerstedt U., French E. D., Schwarcz R. In vivo brain dialysis of amino acids and simultaneous EEG measurements following intrahippocampal quinolinic acid injection: evidence for a dissociation between neurochemical changes and seizures. — J. Neurochem. — 1985. — V. 45. — P. 335-344.

Vezzani A, Wu H. Q., Angelico P. et al. Quinolinic acid-induced seizures, but not nerve cell death, are associated with extracellular Ca2+ decrease assessed in the hippocampus by brain dialysis. — Brain Res. — 1988. — V. 454. — P. 289-297.

Vezzani A., Wu H. Q., Stasi M. A. et al. Effect of various calcium channel blockers on three different models of limbic seizures in rats. — Neuropharmacology. — 1988. -V. 27. — P. 451-458.

Vezzani A, Wu H-Q, Tullii M. et al. Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures but not neurotoxicity induced in rats by quinolinic acid: electroencephalog-raphic, behavioral and histological assessments. — J. Pharmacol, exp. Ther. — 1986. — V. 239. — P. 256-263.

Vojtechovsky M., Kuhn E. Patofyziologie, biochemie a klini-ka spankove deprivace. — Ceskoslov. neurol. a neurochir. — 1980. -V. 43. — P. 81-88.

Volisek L., Roztocilova L., Kusa R. et al. Excitatory amino acids antagonists and pentylenetetrazol-induced seizures during ontho-genesis. 3. The action of kynurenic acid and glutamic acid diethyles-ter. — Brain Res. Bull. — 1995. — V. 38. — P. 525-530.


Wada H., Ito H., Orimo H., Sato A. Kynurenine specifically increases in the cerebrospinal fluid of the aged rats. — Biogenic amines. -1994. -V. 10.-P. 221-226.

Walsh J.-L., Todd W. P., Carpenter В. K., Schwarcz R. 4-ha-lo-3-hyrdoxyanthranilic acids: potent competitive inhibitors of 3-hydroxy-anthranilic acid oxigenase in vitro. — Biochem. Pharmacol. — 1991. — V. 42. — P. 985-990.

Walsh J.-L., Wu H. Q., Ungerstedt V., Schwarcz R. 4-chlo-ro-3-hydroxyanthranilate inhibits quinolinate production in the rat hippocampus in vivo. — Brain Res. Bull. — 1994. — V. 33. — P. 513-516.

Wardley-Smith В., Halsey M. J., Hawley D., Joseph M. The effects of kynurenic acid, quinolinic acid and other metabolites of tryptophan on the development of the high pressure neurological syndrome in the rat. — Neuropharmacology. — 1989. — V. 28. — P. 43-47.

Watanabe M. Distribution of 3-hydroxyanthranilic acid in mice. -Jap. J. Cancer Res. — 1978. — V. 69. — P. 585-587.

Werner E. R., Fuchs D., Hausen A. Tryptophan degradation in patients infected by human immunodeficiency syndrome virus. -Biol. Chem. Hoppe Seyler. — 1988. — V. 369. — P. 3337-340.

Werner E. R., Schennach H., Wachter H., Fuchs D. Simultaneous measurement of serum tryptophan and kynurenine by HPLC. -Clin. Med. — 1997. — V. 43. — P. 2424-2425.

Whetsell W. 0. The use of organotypic tissue culture for study of amino acid neurotoxicity and its antagonism in mammalian CNS. -Clinical Neuropharmacology. — 1984. — V. 7. Suppl. 1. — P. 452-453.

Whetsell W. O., Abou-Kahlil В., Blumenkopf B. et al. Immuno-histochemical study of quinolinic acid catabloism in epileptic human hippocampus. — Soc. Neurosci. Abstr. — 1990. — V. 16. — P. 308.

Whetsel W. O., Schwarcz R. Prolonged exposure to submicromolar concentrations of quinolinic acid causes excitotoxic damage in organotypic cultures of rat corticostriatal system. — Neurosci. Lett. — 1989. — V. 97. — P. 271-275.

Wiley С. A Quinolinic acid and neurodegeneration in AIDS. — J. of Neurovirology. — 1995. — V. 1. — P. 328-329.

Willner P. The validity of animal models of depression. — Psychopharmacology. — 1984. — V. 83. — P. 1-16.

Wolfensberger M., Amsler U. Cuenod M. etal. Identification of quinolinic acid in rat and human brain tissue. Neurosci. Lett. -1983. -V. 41. — P. 247-252.

Wood K., Harwood J., Coppen A The effect of antidepressant drugs on plasma kynurenine in depressed patients. — Psychopharmacology. — 1978. — V. 59. — P. 263-266.

Woodbury D. M., Kemp J. W. Basic mechanisms of seizures: neurophysiological and biochemical etiology. — Psychopathology and Brain Dysfunction (eds. Shagass C., Gershon S., Friedhoff A. J.). — Raven Press. — New York. — 1977. — P. 149-182.

Wu H. Q., Monno A., Schwarcz R., Vezzani A Electrical kindling is associated with a lasting increase in the extracellular levels of kynurenic acid in the rat hippocampus. — Neurosci. Lett. -1995. -V. 198. — P. 91-94.

Wu H. Q., Schwarcz R, Shepard P. D. Excitatory amino acid-induced excitation of dopamine-containing neurons in the rat substantia nigra: modulation by kynurenic acid. — Synapse. -1994. -V. 16. -P. 219-230.

Wu H. Q., Ungerstedt U., Schwarcz R, Regulation of kynurenic acid synthesis studied by microdialysis in the dorsal hippocampus of unanesthetized rats. — Eur. J. Pharmacol. — 1992. — V. 213. -P. 375-380.

Wyatt R J., Zarcone V., Engelman K. et al. Effects of 5-hydro-xytryptophan on the sleep of human subjects. — Electroencephalogr. Clin. Neurophysiol. — 1971. — V. 30. — 505-509.

Yamamoto H., Murakami H., Horiguchi K., Egawa B. Studies on cerebrospinal fluid kynurenic acid concentrations in epileptic children. — Brain and Dvelopment. — 1995. — V. 17. — P. 327-329.

Yamamoto H., Shindo I., Egawa В., Horiguchi К Kynurenic acid is decreased in cerebrospinal fluid of patients with infantile spasm. — Pediatric Neurology. — 1994. — V. 10. — P. 9-12.

Yehuda R., Bierer L. M., Schmeidler J., Aferiat D. H., Brteslau H., Dolan S. Low Cortisol and risk for PTSD in adult offspring of holocaust survivors.-Amer. J. Psychaitry.-2000. — V. 157.-P. 1252-1257.

Yellon R. F., Rose E., Kenna M. A. et al. Sensorineural hearing loss from quinolinic acid: a neurotoxin present in middle ear effusions. — Laryngoscope. — 1994. — V. 104. — P. 176-181.

Yokoi I., Nisijima Y., Uschida A et al. Effect of kynurenine metabolites on the electrocorticographic activity in the rat. — J. Neural Transmission. — 1998. — V. 105. — P. 147-160.

Yokoyama Y., Tada K, ArakawawT. Tryptophan pyrrolase activity in rats subjected to electric convulsions. -Tohoku J. exp. Med. -1968.-V. 96.-P. 199-206.

Yokoyama Y., Tada K, Yoshida T. et al. Liver kynureninase activity of an infant with infantile spasm. — Tohoku J. exp. Med. -1968. -V. 96. — P. 191-198.

Yonekawa W. D., Kupferberg H. J., Woodbury D. M. Relationship between pentylenetetrazol-induced seizures and brain pentylenetetrazol levels in mice. — J. Pharmacol, exp. Ther. -1980. — V. 214. -P. 589-593.

YoungS. N., Joseph M. H., GauthierS. Studies of kynurenine in human cerebrospinal fluid: lowered levels in epilepsy. — J. Neural Transmission. — 1983. — V. 58. — P. 193-204.

Young S. N., Smith S. E., Phil R O. et al. Tryptophan depletion causes a rapid lowering of mood in normal males. — Psychopharmacology. — 1985. — V. 87. — P. 173-177.

Young S. N., Sourkes T. L. The rate of tryptophan oxidation by tryptophan pyrrolase in the rat: effect of tryptophan loads and changes in tryptophan pyrrolase activity. — Acta vitaminologica et enzy-mologica. — 1975. — V. 29. — P. 299-301.

Yuwiler A, Geller Е., Shapiro S. Response differences in some steroid-sensitive hepatic enzymes in the fasting rat. — Canad. J. Physiol. Pharmacol. — 1969. — V. 47. — P. 317-328.

Yuwiler A, Wetterberg L., Geller E., Alterations in induction of tyrosine aminotransferase and tryptophanoxygenase by glucose pretreatment. — Biochimica et biophysica Acta. — 1970. — V. 208. -P. 428-433.

Zarkovsky A. M. The inhibitory effect of endogenous convulsants quinolinic acid and kynurenine on the pentobarbital stimulation of /3H/-flunitrazepam binding. — Pharmacology Biochemistry Behavior. — 1986. — V. 24. -P. 1215-1218.

Zdanova I. V., Wurtman R J. Llynch H.J et al. Sleep-inducing effects pf low dose of melatonin ingested in the evening. — Clin. Pharmacol. Ther. — 1995. — V. 57. — P. 552-558.

Zisapel N. Melatonin receptors revisited. Review article. -J. Neural Transmission. — 1988. — V. 73. — P. 1-5.

К комментариям в ЖЖ

Добавить комментарий

Ваш адрес email не будет опубликован. Обязательные поля помечены *